GSK - Why Biopharmaceutical Player CureVac Shares Are Rising Today | Benzinga
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday.
The company announced interim data from the ongoing Phase 2 study assessing monovalent and bivalent modified vaccine candidates against COVID-19.
Both vaccine candidates are being developed in collaboration with GSK Plc (NYSE: GSK).
Results from the formal interim analysis showed that both vaccine candidates using CureVac's proprietary second-generation mRNA backbone produced meaningful immune responses.
They also produced favorable reactogenicity ...